Total medical devices industry venture financing deals worth $1.6bn were announced in North America in June 2021, led by $276m venture financing of Element Biosciences, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 15.5% over the previous month of $1.93bn and a rise of 55.2% when compared with the last 12-month average of $1.05bn.
North America held a 51.26% share of the global medical devices industry venture financing deal value that totalled $3.18bn in June 2021. With a 51.26% share and deals worth $1.63bn, the US was the top country in North America’s venture financing deal value across medical devices industry.
In terms of venture financing deal activity, North America recorded 57 deals during June 2021, marking a decrease of 9.52% over the previous month and a drop of 9.52% over the 12-month average. The US recorded 57 deals during the month.
North America medical devices industry venture financing deals in June 2021: Top deals
The top five medical devices industry venture financing deals accounted for 51.5% of the overall value during June 2021.
The combined value of the top five medical devices venture financing deals stood at $841m, against the overall value of $1.6bn recorded for the month.
The top five medical devices industry venture financing deals of June 2021 tracked by GlobalData were:
1) Counterpoint Global, Janus Henderson Investors, Logos Global Management, Meritech Capital Partners and T Rowe Price Associates’ $276m venture financing of Element Biosciences
2) The $255m venture financing of InSilico Medicine by B Capital Group Management, Baidu Ventures, Bold Capital Partners, CITIC Industrial Investment Fund Management, Deerfield ManagementLP, Eight Roads Ventures, Formic Ventures, Lake Bleu Capital, Lilly Asia ventures, Maison Capital Group, Mirae Asset Capital, Orbimed Advisors, Pavilion Capital Partners, President International Development, Qiming Venture Partners, Sage Partners, Sequoia Capital China, Sinovation Ventures and Warburg Pincus
3) Baillie Gifford, Fidelity Management & Research and Koch Disruptive Technologies’ $150m venture financing of Shine Medical Technologies
4) The $100m venture financing of SFractyl Laboratories by M28 Capital Management, Maverick Capital and Population Health Partners
5) Decheng Capital, Deerfield ManagementLP, F-Prime, Orbimed Advisors and RA Capital Management’ venture financing of Adela for $60m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.